FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
January 27th 2025The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.
Read More
Payer Coverage Considerations for New Treatments for Alzheimer Disease
Experts discuss how payers can prepare for new treatments and plan adequate coverage for patients with Alzheimer disease.
Watch
Exploring the Influence of Administration Routes on Medical Costs and Caregiver Burden
An overview of how disease-modifying treatments for Alzheimer disease can impact medical costs and caregiver burden.
Watch
Advancements in Alzheimer Disease Treatment: Emerging Drug Candidates
The panel discusses emerging therapies for Alzheimer disease that are currently in development, including donanemab, subcutaneous lecanemab, and ALZ-801.
Watch